PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Abadan Faculty of Medical Sciences, Abadan, Iran.\', \'Department of Epidemiology, Tehran University of Medical Sciences, Tehran, Iran.\', \'Faculty of Medicine, Imperial College London, London, UK.\', \'Department of Translational Medicine, University of Liverpool, UK.\', \'Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute Tehran University of Medical Sciences, Tehran, Iran.\', \'Global Health New Zealand, New Zealand.\', \'Infectious and Tropical Diseases Research Centre, Ahwaz Jundishapur University of Medical Sciences, Ahwaz, Iran.\', \'University of Moratuwa, Moratuwa, Sri Lanka.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1093/jac/dkaa331
?:hasPublicationType
?:journal
  • The Journal of antimicrobial chemotherapy
is ?:pmid of
?:pmid
?:pmid
  • 32812051
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all